Kenji Ishitsuka

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5760403/publications.pdf

Version: 2024-02-01

157 papers	6,176 citations	94269 37 h-index	71532 76 g-index
168 all docs	168 docs citations	168 times ranked	6171 citing authors

#	Article	IF	Citations
1	Cardiac Involvement of Adult T Cell Leukemia/Lymphoma. Internal Medicine, 2022, 61, 1055-1057.	0.3	3
2	Whole-genome landscape of adult T-cell leukemia/lymphoma. Blood, 2022, 139, 967-982.	0.6	44
3	SRT1720 induces SIRT1â€independent cell death in adult Tâ€cell leukemia/lymphoma. FEBS Journal, 2022, 289, 3477-3488.	2.2	7
4	Long-term follow-up of patients with ATL after autologous stem cell transplantation. Bone Marrow Transplantation, 2022, 57, 323-325.	1.3	3
5	Prediction of the risk for graft versus host disease after allogeneic hematopoietic stem cell transplantation in patients treated with mogamulizumab. Leukemia and Lymphoma, 2022, 63, 1701-1707.	0.6	7
6	RLTPR Q575E: A novel recurrent gainâ€ofâ€function mutation in patients with adult Tâ€cell leukemia/lymphoma. European Journal of Haematology, 2021, 106, 221-229.	1.1	3
7	Diagnosis and management of adult T-cell leukemia/lymphoma. Seminars in Hematology, 2021, 58, 114-122.	1.8	6
8	Epidemiology of adult Tâ€cell leukemiaâ€lymphoma in Japan: An updated analysis, 2012â€2013. Cancer Science, 2021, 112, 4346-4354.	1.7	14
9	Clinical significance of the immunoglobulin G heavyâ€chain repertoire in peripheral blood mononuclear cells of adult Tâ€cell leukaemiaâ€“lymphoma patients receiving mogamulizumab. British Journal of Haematology, 2021, 196, 629.	1.2	3
10	Genomic Analysis Focusing on RUNX1-RUNX1T1 in Japanese Patients with AML: HM-Screen-Japan 01. Blood, 2021, 138, 4464-4464.	0.6	1
11	Properties and Distribution of IDH-1/2 Mutations in Acute Myeloid Leukemia By the Comprehensive Genomic Analysis. Blood, 2021, 138, 4447-4447.	0.6	0
12	Pivotal Phase 2 Study of the EZH1 and EZH2 Inhibitor Valemetostat Tosylate (DS-3201b) in Patients with Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma. Blood, 2021, 138, 303-303.	0.6	4
13	A Global Phase 2 Study of Valemetostat Tosylate (Valemetostat) in Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL), Including R/R Adult T-Cell Leukemia/Lymphoma (ATL) - Valentine-PTCL01. Blood, 2021, 138, 2533-2533.	0.6	9
14	Hematologic Malignancies (HM)-Screen-Japan 01: A Mutation Profiling Multicenter Study on Patients with Acute Myeloid Leukemia. Blood, 2021, 138, 4457-4457.	0.6	4
15	Clinical Significance of FLT3 Mutations in a Comprehensive NGS Multicenter Study of AML: HM-Screen-Japan 01. Blood, 2021, 138, 2313-2313.	0.6	1
16	Genomic Analysis of NPM1 Mutation and KMT2A(MLL)-Rearrangement/Amplification in Japanese Patients with Acute Myeloid Leukemia: Hematologic Malignancies (HM)-Screen-Japan 01. Blood, 2021, 138, 4460-4460.	0.6	0
17	Screening of Promising Chemotherapeutic Candidates from Plants against Human Adult T-Cell Leukemia/Lymphoma (VII): Active Principles from Thuja occidentalis L.. Molecules, 2021, 26, 7619.	1.7	4
18	Treatment of aggressive adult T-cell leukemia/lymphoma: a retrospective study in a hospital located in HTLV-1 highly endemic area. International Journal of Hematology, 2020, 111, 234-240.	0.7	4

#	Article	IF	Citations
19	Prognosis of patients with adult Tâ€cell leukemia/lymphoma in Japan: A nationwide hospitalâ€based study. Cancer Science, 2020, 111, 4567-4580.	1.7	37
20	Mogamulizumab for adult T-cell leukemia-lymphoma: a multicenter prospective observational study. Blood Advances, 2020, 4, 5133-5145.	2.5	25
21	Novel Anti-CD70 Antibody Drug Conjugate for the Treatment of Adult T-Cell Leukemia (ATL). Anticancer Research, 2020, 40, 4471-4479.	0.5	2
22	Establishment of a novel diagnostic test algorithm for human T-cell leukemia virus type 1 infection with line immunoassay replacement of western blotting: a collaborative study for performance evaluation of diagnostic assays in Japan. Retrovirology, 2020, 17, 26.	0.9	30
23	Septic vasculitis induces cutaneous involvement of adult Tâ€cell leukemia/lymphoma. International Journal of Dermatology, 2020, 59, e298-e300.	0.5	0
24	Clinical and cytopathological characteristics of HTLVâ€1⁺ hodgkin lymphoma. Cancer Medicine, 2020, 9, 5788-5797.	1.3	2
25	Cell death induced by dorsomorphin in adult Tâ€cell leukemia/lymphoma is AMPKâ€independent. FEBS Journal, 2020, 287, 4005-4015.	2.2	9
26	Screening of Promising Chemotherapeutic Candidates from Plants against Human Adult T-Cell Leukemia/Lymphoma (VI): Cardenolides from <i>Asclepias curassavica</i>. Biological and Pharmaceutical Bulletin, 2020, 43, 1609-1614.	0.6	3
27	Genetic Features of AML with MLL-Rearrangement and NPM1 Mutation: An Interim-Analysis of HM-Screen-Japan 01. Blood, 2020, 136, 35-36.	0.6	0
28	Whole-Genome Analysis of Adult T-Cell Leukemia/Lymphoma. Blood, 2020, 136, 29-30.	0.6	0
29	Essential thrombocytosis attributed to JAK2-T875N germline mutation. International Journal of Hematology, 2019, 110, 584-590.	0.7	11
30	High expression of NAMPT in adult T-cell leukemia/lymphoma and anti-tumor activity of a NAMPT inhibitor. European Journal of Pharmacology, 2019, 865, 172738.	1.7	21
31	Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report. Journal of Clinical Oncology, 2019, 37, 677-687.	0.8	162
32	A survivin-responsive, conditionally replicating adenovirus induces potent cytocidal effects in adult T-cell leukemia/lymphoma. BMC Cancer, 2019, 19, 516.	1.1	6
33	Possibility of a riskâ€adapted treatment strategy for untreated aggressive adult Tâ€cell leukaemiaâ€lymphoma (<scp>ATL</scp>) based on the <scp>ATL</scp> prognostic index: a supplementary analysis of the <scp>JCOG</scp>9801. British Journal of Haematology, 2019, 186, 440-447.	1.2	8
34	Safety and effectiveness of mogamulizumab in relapsed or refractory adult Tâ€cell leukemiaâ€lymphoma. European Journal of Haematology, 2019, 102, 407-415.	1.1	17
35	A retrospective analysis of haplo-identical HLA-mismatch hematopoietic transplantation without posttransplantation cyclophosphamide for GVHD prophylaxis in patients with adult T-cell leukemiaâ€“lymphoma. Bone Marrow Transplantation, 2019, 54, 1266-1274.	1.3	14
36	Followâ€up of a randomised phase II study of chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult Tâ€cell leukaemiaâ€lymphoma: impact on allogeneic haematopoietic stem cell transplantation. British Journal of Haematology, 2019, 184, 479-483.	1.2	29

#	Article	IF	Citations
37	A Novel Recurrent Gain-of-Function Mutation of Rltpr Q575E in Adult T Cell Leukemia/Lymphoma. Blood, 2019, 134, 1489-1489.	0.6	1
38	First-in-Human Study of the EZH1/2 Dual Inhibitor Valemetostat in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) - Updated Results Focusing on Adult T-Cell Leukemia-Lymphoma (ATL). Blood, 2019, 134, 4025-4025.	0.6	13
39	Clinical significance of cutaneous adverse reaction to mogamulizumab in relapsed or refractory adult Tâ€cell leukaemiaâ€lymphoma. British Journal of Haematology, 2018, 181, 539-542.	1.2	14
40	Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma. Blood, 2018, 131, 215-225.	0.6	124
41	The difficulty in establishing clinical evidence of extremely-rare hematological malignancies. Annals of Oncology, 2018, 29, vii41.	0.6	0
42	Development of reference material with assigned value for human Tâ€cell leukemia virus type 1 quantitative PCR in Japan. Microbiology and Immunology, 2018, 62, 673-676.	0.7	8
43	Pre- and posttransplant use of mogamulizumab in patients with aggressive adult T-cell leukemia-lymphoma: A statement from key opinion leaders in Japan. Advances in Cell and Gene Therapy, 2018, 1, e5.	0.6	4
44	DS-3201, a Potent EZH1/2 Dual Inhibitor, Demonstrates Antitumor Activity Against Non-Hodgkin Lymphoma (NHL) Regardless of EZH2 Mutation. Blood, 2018, 132, 2217-2217.	0.6	9
45	The small molecule STF-62247 induces apoptotic and autophagic cell death in leukemic cells. Oncotarget, 2018, 9, 27645-27655.	0.8	6
46	Possibility of a Risk-Adapted Treatment Strategy for Untreated Aggressive Adult T-Cell Leukemia-Lymphoma (ATL) Based on the ATL Prognostic Index: A Supplementary Analysis of the JCOG9801 Study. Blood, 2018, 132, 1645-1645.	0.6	0
47	Treatment of Indolent Adult T-cell Leukemia/Lymphoma (ATL). , 2017, , 117-124.		0
48	C-MYC and Its Main Ubiquitin Ligase, FBXW7, Influence Cell Proliferation and Prognosis in Adult T-cell Leukemia/Lymphoma. American Journal of Surgical Pathology, 2017, 41, 1139-1149.	2.1	22
49	Prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma. Blood, 2017, 130, 39-47.	0.6	43
50	Safety and efficacy of mogamulizumab in patients with adult T-cell leukemiaâ€“lymphoma in Japan: interim results of postmarketing all-case surveillance. International Journal of Hematology, 2017, 106, 522-532.	0.7	28
51	Epidemiological and clinical features of adult Tâ€cell leukemiaâ€“lymphoma in Japan, 2010â€“2011: A nationwide survey. Cancer Science, 2017, 108, 2478-2486.	1.7	63
52	BK-UM in patients with recurrent ovarian cancer or peritoneal cancer: a first-in-human phase-I study. BMC Cancer, 2017, 17, 89.	1.1	8
53	Screening of promising chemotherapeutic candidates from plants against human adult T-cell leukemia/lymphoma (V): coumarins and alkaloids from Boenninghausenia japonica and Ruta graveolens. Journal of Natural Medicines, 2017, 71, 170-180.	1.1	7
54	Treatment advances and prognosis for patients with adult T-cell leukemia-lymphoma. Journal of Clinical and Experimental Hematopathology: JCEH, 2017, 57, 87-97.	0.3	26

#	Article	IF	Citations
55	V. Adult T-cell Leukemia: Diagnosis and Treatment. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 1397-1403.	0.0	0
56	High Expression of Intestinal Homing Receptor CD103 in Adult T-Cell Leukemia/Lymphoma, Similar to 2 Other CD8+ T-Cell Lymphomas. American Journal of Surgical Pathology, 2016, 40, 462-470.	2.1	12
57	FoxP3â€positive T cell lymphoma arising in nonâ€HTLV1 carrier: clinicopathological analysis of 11 cases of PTCLâ€NOS and 2 cases of mycosis fungoides. Histopathology, 2016, 68, 1099-1108.	1.6	10
58	Treatment and Prognosis in Patients with Adult T-Cell Leukemia-Lymphoma (ATL): A Nationwide Survey in Japan. Blood, 2016, 128, 5936-5936.	0.6	0
59	Impact of Chromosomal Abnormalities in Acute and Lymphoma Types Adult T-Cell Leukemia-Lymphoma. Blood, 2016, 128, 4123-4123.	0.6	0
60	OPEC/Mpec for Adult T-Cell Leukemia/Lymphoma: A Single-Institution Study. Blood, 2016, 128, 1828-1828.	0.6	0
61	Treatment and survival among 1594 patients with ATL. Blood, 2015, 126, 2570-2577.	0.6	244
62	A phase <scp>II</scp> study of bortezomib in patients with relapsed or refractory aggressive adult Tâ€cell leukemia/lymphoma. Cancer Science, 2015, 106, 1219-1223.	1.7	28
63	Screening of promising chemotherapeutic candidates from plants against human adult T-cell leukemia/lymphoma (IV): phenanthroindolizidine alkaloids from Tylophora tanakae leaves. Journal of Natural Medicines, 2015, 69, 397-401.	1.1	10
64	Doseâ€intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult Tâ€cell leukaemiaâ€lymphoma: a randomized phase <scp>II</scp> study. British Journal of Haematology, 2015, 169, 672-682.	1.2	218
65	Colitis mimicking graft-versus-host disease during treatment with the anti-CCR4 monoclonal antibody, mogamulizumab. International Journal of Hematology, 2015, 102, 493-497.	0.7	12
66	Prognostic index for chronic and smoldering types adult T-cell leukemia/lymphoma.. Journal of Clinical Oncology, 2015, 33, 8522-8522.	0.8	1
67	Current Clinico-Epidemiological Characteristics of Adult T-Cell Leukemia-Lymphoma (ATL) Based on the 11th Nationwide Survey in Japan. Blood, 2015, 126, 5034-5034.	0.6	0
68	Is Watch and Wait Still Standard for Indolent Atl?. Annals of Oncology, 2014, 25, v26.	0.6	0
69	Febrile Neutropenia(Fn)And D-Index. Annals of Oncology, 2014, 25, v42.	0.6	0
70	Polypharmacy in Elderly Cancer Patients. Annals of Oncology, 2014, 25, v100.	0.6	1
71	Evaluation of regional cerebral glucose metabolism in patients with malignant lymphoma of the body using statistical image analysis. Annals of Nuclear Medicine, 2014, 28, 950-960.	1.2	10
72	Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long-term survivors of aggressive adult T-cell leukaemia-lymphoma (JCOG0902A). British Journal of Haematology, 2014, 166, 739-748.	1.2	79

#	Article	IF	Citations
73	Gene expression profiling of Epsteinâ€“Barr virusâ€positive diffuse large Bâ€cell lymphoma of the elderly reveals alterations of characteristic oncogenetic pathways. Cancer Science, 2014, 105, 537-544.	1.7	61
74	Safety and pharmacokinetic evaluation of repeated intravenous administration of palonosetron 0.75Âmg in patients receiving highly or moderately emetogenic chemotherapy. Supportive Care in Cancer, 2014, 22, 1959-1964.	1.0	9
75	Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma. Lancet Oncology, The, 2014, 15, e517-e526.	5.1	282
76	Promise of combining a Bcl-2 family inhibitor with bortezomib or SAHA for adult T-cell leukemia/lymphoma. Anticancer Research, 2014, 34, 5287-94.	0.5	16
77	Screening of promising chemotherapeutic candidates from plants against human adult T-cell leukemia/lymphoma (III). Journal of Natural Medicines, 2013, 67, 894-903.	1.1	23
78	Screening of promising chemotherapeutic candidates from plants against human adult T-cell leukemia/lymphoma (II): apoptosis of antiproliferactive principle (24,25-dihydrowithanolide D) against ATL cell lines and structureâ€“activity relationships with withanolides isolated from solanaceous plants. Journal of Natural Medicines, 2013, 67, 415-420.	1.1	11
79	Randomized phase II study of mogamulizumab (KW-0761) plus VCAP-AMP-VECP (mLSG15) versus mLSG15 alone for newly diagnosed aggressive adult T-cell leukemia-lymphoma (ATL).. Journal of Clinical Oncology, 2013, 31, 8506-8506.	0.8	11
80	Prognostic Index for Acute- and Lymphoma-Type Adult T-Cell Leukemia/Lymphoma. Journal of Clinical Oncology, 2012, 30, 1635-1640.	0.8	160
81	Defucosylated Anti-CCR4 Monoclonal Antibody (KW-0761) for Relapsed Adult T-Cell Leukemia-Lymphoma: A Multicenter Phase II Study. Journal of Clinical Oncology, 2012, 30, 837-842.	0.8	581
82	Reply to J.J. Castillo et al. Journal of Clinical Oncology, 2012, 30, 3561-3561.	0.8	1
83	Targeting Bcl-2 family proteins in adult T-cell leukemia/lymphoma: In vitro and in vivo effects of the novel Bcl-2 family inhibitor ABT-737. Cancer Letters, 2012, 317, 218-225.	3.2	32
84	First reported case of hemoglobin lansing in Asia detected by false low oxygen saturation on pulse oximetry. International Journal of Hematology, 2012, 95, 731-732.	0.7	6
85	Screening of promising chemotherapeutic candidates against human adult T-cell leukemia/lymphoma from plants: active principles from Physalis pruinosa and structureâ€“activity relationships with withanolides. Journal of Natural Medicines, 2011, 65, 559-567.	1.1	17
86	Characterization of Long-Term Survivors and a Predictive Model for Aggressive Adult T-Cell Leukemia-Lymphoma (ATL): An Ancillary Study by the Japan Clinical Oncology Group, JCOG0902A. Blood, 2011, 118, 881-881.	0.6	3
87	Interferon-alpha and antiretroviral agents: a treatment option for adult T-cell leukemia/lymphoma. , 2011, 47, 615.		4
88	Interferon-Î± and zidovudine for relapsed/refractory adult T cell leukemia/lymphoma: case reports of Japanese patients. International Journal of Hematology, 2010, 92, 762-764.	0.7	6
89	Is Zidovudine and Interferon-Alfa the Gold Standard for Adult T-Cell Leukemia-Lymphoma?. Journal of Clinical Oncology, 2010, 28, e765-e765.	0.8	9
90	Multicenter Phase II Study of KW-0761, a Defucosylated Anti-CCR4 Antibody, In Relapsed Patients with Adult T-Cell Leukemia-Lymphoma (ATL). Blood, 2010, 116, 285-285.	0.6	8

#	Article	IF	Citations
91	A patient with acute myeloid leukemia who developed fatal pneumonia caused by carbapenem-resistant Bacillus cereus. Journal of Infection and Chemotherapy, 2009, 15, 39-41.	0.8	21
92	Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma. Leukemia and Lymphoma, 2009, 50, 1818-1823.	0.6	52
93	Cladribine Treatment in Two-Hour Intravenous Infusion for Previously-Treated Low Grade B-Cell Lymphoma : A Pilot Study. Journal of Clinical and Experimental Hematopathology: JCEH, 2009, 49, 69-75.	0.3	1
94	Targeting Bcl-2 Family Proteins in Adult T-Cell Leukemia/Lymphoma: In Vitro and In Vivo Effects of a Novel Bcl-2 Family Inhibitor ABT-737.. Blood, 2009, 114, 1685-1685.	0.6	0
95	Targeting CD56 by the maytansinoid immunoconjugate IMGN901 (huN901â€DM1): a potential therapeutic modality implication against natural killer/T cell malignancy. British Journal of Haematology, 2008, 141, 129-131.	1.2	34
96	p38 mitogenâ€activated protein kinase inhibitor LY2228820 enhances bortezomibâ€induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications. British Journal of Haematology, 2008, 141, 598-606.	1.2	53
97	Smouldering adult Tâ€cell leukaemia/lymphoma: a followâ€up study in Kyushu. British Journal of Haematology, 2008, 143, 442-444.	1.2	20
98	Treatment of adult Tâ€cell leukemia/lymphoma: past, present, and future. European Journal of Haematology, 2008, 80, 185-196.	1.1	73
99	Aggressive NK cell leukaemia after splenectomy: association with CD95â€resistant memory Tâ€cell proliferation and recalcitrant clinical course of haemophagocytic syndrome. European Journal of Haematology, 2008, 81, 236-241.	1.1	5
100	A Promising Therapeutic Implication of a Novel Bcl-2 Family Inhibitor ABT-737 for Adult T-Cell Leukemia/Lymphoma.. Blood, 2008, 112, 1584-1584.	0.6	0
101	5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Molecular Cancer Therapeutics, 2007, 6, 1718-1727.	1.9	154
102	MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. Blood, 2007, 110, 3744-3752.	0.6	144
103	Therapeutic potential of arsenic trioxide with or without interferon-Â for relapsed/refractory adult T-cell leukemia/lymphoma. Haematologica, 2007, 92, 719-720.	1.7	21
104	JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells. Blood, 2007, 110, 709-718.	0.6	139
105	BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth. British Journal of Haematology, 2007, 136, 414-423.	1.2	49
106	The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 19478-19483.	3.3	189
107	Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood, 2006, 107, 4053-4062.	0.6	398
108	FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma. British Journal of Haematology, 2006, 132, 698-704.	1.2	4

#	Article	IF	Citations
109	In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells. British Journal of Haematology, 2006, 134, 37-44.	1.2	18
110	MLN120B, a Novel ÎºB Kinase Î² Inhibitor, Blocks Multiple Myeloma Cell Growth In vitro and In vivo. Clinical Cancer Research, 2006, 12, 5887-5894.	3.2	130
111	Bortezomib Mediates Antiangiogenesis in Multiple Myeloma via Direct and Indirect Effects on Endothelial Cells. Cancer Research, 2006, 66, 184-191.	0.4	266
112	MLN3897, a Novel CCR1 Antagonist, Inhibits Osteoclastogenesis by Blocking Early ERK Activation.. Blood, 2006, 108, 1636-1636.	0.6	0
113	Akt Inhibitor Perifosine-Induced Cytotoxicity Is Associated with Significant Downregulation of Survivin in Human Multiple Myeloma (MM) Cells.. Blood, 2006, 108, 3410-3410.	0.6	0
114	The Small-Molecule VEGF-Receptor Inhibitor Pazopanib (GW786034B) Targets Both Tumor and Endothelial Cells in Multiple Myeloma.. Blood, 2006, 108, 5003-5003.	0.6	0
115	BIRB796 Inhibits p38 MAPK/Hsp27 Pathway and Enhances Cytotoxicity Triggered by Bortezomib, Hsp90 Inhibitor, and Dexamethasone in Multiple Myeloma.. Blood, 2006, 108, 3440-3440.	0.6	0
116	Serotonin Receptor Antagonists Have an In Vitro and In Vivo Anti-Myeloma Effect That Is Mainly Mediated by Caspase Dependent Apoptosis.. Blood, 2006, 108, 2597-2597.	0.6	2
117	CCR1 Inhibition Impairs Osteoclast Activity and Interaction with Myeloma Cells.. Blood, 2006, 108, 3494-3494.	0.6	5
118	Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood, 2005, 106, 1042-1047.	0.6	172
119	Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis. Blood, 2005, 106, 1794-1800.	0.6	167
120	SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. Blood, 2005, 106, 706-712.	0.6	54
121	Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. Blood, 2005, 105, 4470-4476.	0.6	59
122	Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-Î² inhibitors. Oncogene, 2005, 24, 3121-3129.	2.6	43
123	Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway. Oncogene, 2005, 24, 5888-5896.	2.6	56
124	FTY720 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Drug Resistance. Cancer Research, 2005, 65, 7478-7484.	0.4	97
125	The Role of B Cell-Activating Factor (BAFF) in the Biology of Multiple Myeloma (MM).. Blood, 2005, 106, 3380-3380.	0.6	3
126	JS-K, a GST-Activated Nitric Oxide Generator, Induces Apoptosis and Overcomes In Vitro Drug Resistance in Multiple Myeloma Cells.. Blood, 2005, 106, 1593-1593.	0.6	0

#	Article	IF	Citations
127	Up-Regulation of c-Jun contributes to the Induction of Apoptosis by Adaphostin in Human Multiple Myeloma Cells.. Blood, 2005, 106, 1585-1585.	0.6	0
128	Didox Induced Apoptosis Occurs by Inhibiting DNA Synthesis and Repair Via Down-Regulation of Ribonucleotide Reductase M1 in Multiple Myeloma (MM).. Blood, 2005, 106, 5153-5153.	0.6	0
129	Transforming Growth Factor Î² Receptor I Kinase Inhibitor Down-Regulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment. Clinical Cancer Research, 2004, 10, 7540-7546.	3.2	111
130	Mechanisms by which SGN-40, a Humanized Anti-CD40 Antibody, Induces Cytotoxicity in Human Multiple Myeloma Cells: Clinical Implications. Cancer Research, 2004, 64, 2846-2852.	0.4	126
131	Caveolin-1 Is Required for Vascular Endothelial Growth Factor-Triggered Multiple Myeloma Cell Migration and Is Targeted by Bortezomib. Cancer Research, 2004, 64, 7500-7506.	0.4	86
132	p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene, 2004, 23, 8766-8776.	2.6	127
133	Bone marrow necrosis in a patient with acute promyelocytic leukemia during re-induction therapy with arsenic trioxide. European Journal of Haematology, 2004, 72, 280-284.	1.1	18
134	VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis. Blood, 2004, 104, 2886-2892.	0.6	147
135	Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood, 2004, 104, 4188-4193.	0.6	177
136	Mitochondria and Caspase-Independent Cell-Death Triggered by GCS-100, a Novel Carbohydrate-Based Therapeutic in Multiple Myeloma (MM) Cells.. Blood, 2004, 104, 2456-2456.	0.6	1
137	Honokiol Overcomes Conventional Drug Resistance in Human Multiple Myeloma.. Blood, 2004, 104, 1488-1488.	0.6	0
138	Atiprimod (N-N-diethl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) Inhibits Myeloma in Vivo.. Blood, 2004, 104, 2401-2401.	0.6	0
139	Targeting IKK Inhibits Multiple Myeloma (MM) Cell Growth in the Bone Marrow Microenvironment.. Blood, 2004, 104, 2351-2351.	0.6	0
140	SDX-101 Is Cytotoxic and Overcomes Drug Resistance in Multiple Myeloma.. Blood, 2004, 104, 3466-3466.	0.6	0
141	VEGF Upregulates Mcl-1 Expression and Protects Multiple Myeloma Cells Against Starvation Induced-Apoptosis.. Blood, 2004, 104, 631-631.	0.6	0
142	Combination of the mTOR Inhibitor Rapamycin and Revlimidâ„¢ (CC-5013) Has Synergistic Activity in Multiple Myeloma (MM).. Blood, 2004, 104, 1492-1492.	0.6	1
143	TGF-Î² Receptor I Kinase Inhibitor Downregulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment.. Blood, 2004, 104, 2355-2355.	0.6	1
144	Bortezomib Targets Multiple Myeloma Endothelial Cells.. Blood, 2004, 104, 4903-4903.	0.6	0

#	Article	IF	Citations
145	Anti-Tumor Activity of a Novel Immunosuppressant FTY720 in Multiple Myeloma.. Blood, 2004, 104, 3456-3456.	0.6	0
146	P38 MAPK Inhibition Enhances PS-341 (bortezomib)-Induced Cytotoxicity Against Multiple Myeloma Cells.. Blood, 2004, 104, 3348-3348.	0.6	0
147	In Vitro Activity of a Novel Small Molecule Cyclin Dependent Kinase Inhibitor, CYC202 (seliciclib or) Tj ETQq1 1 0.784314 rgBT /Overlock	0.6	0
148	Endothelial Cells Induce Multiple Myeloma Cell Proliferation Protect Against Conventional and Novel Therapies.. Blood, 2004, 104, 2354-2354.	0.6	1
149	The Tyrosine Kinase Inhibitor Adaphostin (NSC 680410), but Not Imatinib Mesylate, Inhibits Survival and Src Tyrosine Kinase Family- Triggered Signaling Pathways of MM Cells.. Blood, 2004, 104, 3352-3352.	0.6	1
150	Arsenic Trioxide Induces Apoptosis in HTLV-I Infected T-cell Lines and Fresh Adult T-cell Leukemia Cells Through CD95 or Tumor Necrosis Factor Î± Receptor Independent Caspase Activation. Leukemia and Lymphoma, 2002, 43, 1107-1114.	0.6	22
151	Inhibition by arsenic trioxide of human hepatoma cell growth. Cancer Letters, 2002, 183, 147-153.	3.2	68
152	Arsenic Trioxide and the Growth of Human T-cell Leukemia Virus Type I Infected T-cell Lines. Leukemia and Lymphoma, 2000, 37, 649-655.	0.6	28
153	Arsenic trioxide inhibits growth of human T-cell leukaemia virus type I infected T-cell lines more effectively than retinoic acids. British Journal of Haematology, 1998, 103, 721-728.	1.2	49
154	Expression of the intestinal T-lymphocyte-associated-molecule recognized by the HML-1 antibody on mononuclear cells from HTLV-I-infected subjects. American Journal of Hematology, 1995, 50, 1-8.	2.0	7
155	Significance of Elevated Levels of Soluble Factors in the Cerebrospinal Fluid in Patients with, Adult T-cell Leukemia. Leukemia and Lymphoma, 1995, 19, 437-445.	0.6	6
156	Combination Chemotherapy (RCM Protocol: Response-Oriented Cyclic Multidrug Protocol) For the Acute or Lymphoma Type Adult T-cell Leukemia. Leukemia and Lymphoma, 1995, 18, 317-323.	0.6	25
157	Elevated soluble CD4 levels in the cerebrospinal fluid in patients with adult T-cell leukemia. American Journal of Hematology, 1994, 46, 95-100.	2.0	4